The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Side-effect management › BRAF/MEK inhibitors and statins › Reply To: BRAF/MEK inhibitors and statins
December 13, 2017 at 7:49 pm #4558
Expert NurseLisa Kottschade
Hi Virginia, Agree the vedolizumab would have been ideal and we’ve done this in several patients. Have you tried to appeal to the company via a patient assistance program? We were able to get this paid for via this route for one patient. Additionally we had one patient that ended up having some really uncommon sort of pathogen and we were able treat with antibiotics and she had significant improvement and was able to wean off the steroids.